Prevención de la diabetes mellitus en los pacientes con insuficiencia cardiaca

Medrano, 2005, Factores de riesgo cardiovascular en la población española: metaanálisis de estudios transversales, Med Clin (Barc), 124, 606, 10.1157/13074389 2005, Position Statement: Standards of Medical Care in Diabetes, Diabetes Care, 28, S4, 10.2337/diacare.28.suppl_1.S4 Barrios, 2002, Diabetes y corazón, Hipertensión, 19, 28 Laakso, 1999, Hyperglycemia and cardiovascular disease in type 2 diabetes, Diabetes, 48, 937, 10.2337/diabetes.48.5.937 Neil, 1993, A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM, Diabetes Care, 16, 996, 10.2337/diacare.16.7.996 Barrios, 2001, Enfermedad cardiovascular y diabetes, 83 Gu, 1999, Diabetes and decline in heart disease mortality in US adults, JAMA, 281, 1291, 10.1001/jama.281.14.1291 Kannel, 1974, Role of diabetes in congestive heart failure. The Framingham Study, Am J Cardiol, 34, 29, 10.1016/0002-9149(74)90089-7 Ingelsson, 2005, Insulin resistance and risk of congestive heart failure, JAMA, 294, 334, 10.1001/jama.294.3.334 González-Juanatey, 2001, Impacto de la diabetes en las enfermedades cardiacas en España. Estudio CARDIOTENS 1999, Med Clin (Barc), 116, 686, 10.1016/S0025-7753(01)71953-7 Barrios, 2003, Hipertensión arterial e insuficiencia cardiaca en las consultas de atención primaria y de cardiología en España, Rev Clin Esp, 203, 334, 10.1157/13047947 Duggirala, 2005, Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics, Am J Hypertens, 18, 833, 10.1016/j.amjhyper.2004.12.016 Álvarez-Sala, 2005, Estudio PREVENCAT: Control del riesgo cardiovascular en Atención Primaria, Med Clin (Barc), 124, 406, 10.1157/13072841 Barrios, 2003, Efectividad antihipertensiva y tolerabilidad de lercanidipino en diabéticos, en pacientes con hipertensión sistólica aislada y en ancianos. Análisis de subgrupos del estudio ELYPSE, Hipertensión, 20, 347 Flather, 2000, Lomg-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group, Lancet, 355, 1575, 10.1016/S0140-6736(00)02212-1 Eguchi, 2005, Type 2 diabetes is associated with left ventricular concentric remodelling in hypertensive patients, AM J Hypertens, 7, 221 Aguilar, 2004, Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the Valsartan in acute myocardial infarction (VALIANT) Trial, Circulation, 110, 1572, 10.1161/01.CIR.0000142047.28024.F2 Verdecchia, 2004, Adverse prognostic significance of new diabetes in treated hypertensive subjects, Hypertension, 43, 963, 10.1161/01.HYP.0000125726.92964.ab Lindholm, 2002, Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study, J Hypertens, 20, 1879, 10.1097/00004872-200209000-00035 Abuissa, 2005, Strategies to prevent type 2 diabetes, Curr Med Res Opin, 21, 1107, 10.1185/030079905X50606 Barrios, 2000, Hypertension with left ventricular hypertrophy/diastolic dysfunction, 16 Messerli, 2004, Antihypertensive therapy and new onset diabetes, J Hypertens, 22, 1845, 10.1097/00004872-200410000-00001 Bristow, 1996, Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure, Circulation, 94, 2807, 10.1161/01.CIR.94.11.2807 Gress, 2000, Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk In Communities (ARIC) study, N Engl J Med, 342, 905, 10.1056/NEJM200003303421301 Ruilope, 2001, Pharmacologic treatment. Section 3: CK Francis, GYJ Lip. Hypertensive Heart Disease, 8.1 Bakris, 2004, Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized contyrolled trial, JAMA, 292, 2227, 10.1001/jama.292.18.2227 Poole-Wilson, 2003, Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial, Lancet, 362, 7, 10.1016/S0140-6736(03)13800-7 Mancia, 2003, Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT), Hypertension, 41, 431, 10.1161/01.HYP.0000057420.27692.AD Hansson, 2000, Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study, Lancet, 356, 359, 10.1016/S0140-6736(00)02526-5 Pepine, 2003, A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial, JAMA, 290, 2805, 10.1001/jama.290.21.2805 Hansson, 1999, Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study, Lancet, 354, 1751, 10.1016/S0140-6736(99)10327-1 2002, JAMA, 288, 2981, 10.1001/jama.288.23.2981 Barrios, 1999, ACE inhibitors in the treatment of heart failure [letter], Heart Failure, 7, 2 Shindler, 1996, Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction trials and registry, Am J Cardiol, 77, 1017, 10.1016/S0002-9149(97)89163-1 2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE and micro-HOPE study, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7 Hansson, 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0 Yusuf, 2001, Ramipril and the development of diabetes, JAMA, 286, 1882, 10.1001/jama.286.15.1882 2004, Angiotensin converting-enzyme inhibition in stable coronary artery disease, New Engl J Med, 351, 2058, 10.1056/NEJMoa042739 Wing, 2003, A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly, N Engl J Med, 348, 583, 10.1056/NEJMoa021716 Barrios, 2005, Papel de los ARA-II en el tratamiento de la hipertensión arterial. De la evidencia a la práctica clínica, Clin Invest Arterioscl, 17, S70 Barrios, 2003, Utilidad de los ARA-II en la insuficiencia cardiaca, Rev Clin Esp, 203, 28, 10.1157/13042186 Ruilope, 2000, Renal implications of the reninangiotensin-aldosterone system blockade in heart failure, J Hypertens, 18, 1545, 10.1097/00004872-200018110-00003 Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 Lindholm, 2003, Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study), J Hypertens, 21, 1563, 10.1097/00004872-200308000-00022 Lithell, 2003, The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial, J Hypertens, 21, 875, 10.1097/00004872-200305000-00011 Lithell, 2004, The study on cognition and prognosis in the elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomisation, J Hypertens, 22, 1605, 10.1097/01.hjh.0000133730.47372.4c Kjeldsen, 2001, Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation, Blood Press, 10, 83, 10.1080/08037050152112069 Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9 Yusuf, 2005, Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure, Circulation, 112, 48, 10.1161/CIRCULATIONAHA.104.528166 McMurray, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial, Lancet, 362, 767, 10.1016/S0140-6736(03)14283-3 Granger, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5 Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7 Opie, 2004, Old antihypertensives and new diabetes, J Hypertens, 22, 1453, 10.1097/01.hjh.0000133732.24501.9e Sharma, 2002, Angiotensin blockade prevents type 2 diabetes by formation of fat cells, Hypertension, 40, 609, 10.1161/01.HYP.0000036448.44066.53 Carlsson, 1998, Angiotensin and endocrine pancreas: effect on islet blood flow and insulin secretion in rats, Diabetologia, 41, 127, 10.1007/s001250050880 Gillespie, 2005, The impact of ACE inhibitors or Angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes, Diabetes Care, 28, 2261, 10.2337/diacare.28.9.2261 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512 Chiasson, 2003, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial, JAMA, 290, 486, 10.1001/jama.290.4.486 Buchanan, 2002, Preservation of pancreatio beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin-resistance in high-risk Hispanic women, Diabetes, 51, 2796, 10.2337/diabetes.51.9.2796 Padwal, 2005, A systematic review of drug therapy or prevent type 2 diabetes, Diabetes Care, 28, 736, 10.2337/diacare.28.3.736 Kjekshus, 2005, A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics, Eur J Heart Fail, 7, 1059, 10.1016/j.ejheart.2005.09.005